Condition (MeSH)
Tics
ClinicalTrials.gov lists 64 trials for Tics or a narrower condition beneath it. National Institute of Neurological Disorders and Stroke (NINDS) has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
64 of the 64 trials are tagged with Tics itself; the rest are tagged with a narrower condition beneath it.
When did Tics trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 4 |
| 2024 | 2 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 4 |
| 2020 | 4 |
| 2019 | 3 |
| 2018 | 3 |
| 2017 | 2 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 2.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 41 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Tics trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 8 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |
| Phase 4 | 4 |
| Not applicable | 32 |
| Observational | 12 |
How many Tics trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 8 |
| Enrolling by invitation | 1 |
| Completed | 41 |
| Terminated | 5 |
| Withdrawn | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Tics trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | 6 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 |
Which drugs are being tested for Tics? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Aripiprazole | 2 |
| EPI-743 | 1 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Active drug: pimavanserin 17mg (2 strength tablets) | 1 |
| fatty acids, omega-3 | 1 |
| Abobotulinum toxin A | 1 |
| 1% Azithromycin | 1 |
| Galantamine ER | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Tics trials report? (6)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Appendicitis | 1 | 1 |
| Concussion | 1 | 1 |
| Infectious mononucleosis | 1 | 1 |
| Intentional overdose | 1 | 1 |
| Tourette's disorder | 1 | 1 |
Showing 5 of 6 adverse events.
Which publications cover Tics? (98)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Sleep and daytime functioning in children with tourette syndrome: A two-week case-control study with actigraphy and cognitive assessments. | Sleep medicine | 2024 | Yes |
| The COVID-19 pandemic and its impact on tic symptoms in children and young people: a prospective cohort study. | Child psychiatry and human development | 2023 | Yes |
| A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome. | Cannabis and cannabinoid research | 2023 | Yes |
| Tourette syndrome: clinical features, pathophysiology, and treatment. | The Lancet. Neurology | 2023 | Yes |
| How does Tourette syndrome impact adolescents' daily living? A text mining study. | European child & adolescent psychiatry | 2023 | Yes |
Showing 5 of 98 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.